Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

A number of other equities research analysts have also recently issued reports on AUPH. Cantor Fitzgerald initiated coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, April 10th. They set an “overweight” rating and a $14.00 target price for the company. FBR & Co reiterated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, April 11th. HC Wainwright dropped their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Vetr cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price for the company. in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $9.28.

Shares of Aurinia Pharmaceuticals (AUPH) traded down 1.49% during mid-day trading on Tuesday, hitting $5.95. 948,246 shares of the stock were exchanged. The firm’s market cap is $495.47 million. Aurinia Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $10.54. The company’s 50-day moving average is $6.40 and its 200-day moving average is $6.03.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%. Equities research analysts anticipate that Aurinia Pharmaceuticals will post ($0.74) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/08/aurinia-pharmaceuticals-inc-nasdaqauph-rating-increased-to-hold-at-zacks-investment-research.html.

A number of large investors have recently bought and sold shares of the stock. NEA Management Company LLC boosted its stake in Aurinia Pharmaceuticals by 18.2% in the first quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock valued at $35,294,000 after buying an additional 740,740 shares during the last quarter. AWM Investment Company Inc. bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at $2,202,000. Quantbot Technologies LP bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at $275,000. Two Sigma Securities LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at $240,000. Finally, OTA Financial Group L.P. bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at $1,291,000. Hedge funds and other institutional investors own 29.48% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.